Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia (CBF-AML). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to an antitumor antibiotic drug, called ozogamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers ozogamicin to kill them. Chemotherapy drugs, such as cytarabine and daunorubicin work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax with cytarabine and daunorubicin may have fewer side effects and be as effective or better than the combination with gemtuzumab ozogamicin in treating patients with core binding factor AML.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent musi być zarejestrowany do programu MYELOMATCH i zakwalifikowany do tego badania.
- •Pacjent nie może być wcześniej leczony z powodu ostrej białaczki szpikowej (AML) lub zespołu mielodysplastycznego (MDS).
- •Możliwe jest otrzymanie hydroksymocznika w celu kontroli liczby białych krwinek lub do 1g cytarabiny w nagłych przypadkach.
- •Stosowanie leków stymulujących produkcję czerwonych krwinek nie jest traktowane jako wcześniejsze leczenie.
- •Potwierdzony typ ostrej białaczki szpikowej CBF-AML.
- •Wiek od 18 do 59 lat.
- •Ogólny stan zdrowia pacjenta (ECOG) nie gorszy niż 3.
- •Prawidłowe wyniki badań wątroby i nerek.
✗ Disqualifies
- •Pacjenci, którzy otrzymali jakiekolwiek leczenie z powodu AML lub MDS, z wyjątkiem nagłego leczenia wysokiej liczby białych krwinek.
- •Obecność mutacji FLT3.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 59 Years
- Last updated (source)
- August 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (40)
Memorial Hospital West
Pembroke Pines, United States
Kootenai Health - Coeur d'Alene
Coeur d'Alene, United States
Kootenai Clinic Cancer Services - Post Falls
Post Falls, United States
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, United States
Northwestern University
Chicago, United States
University of Kansas Clinical Research Center
Fairway, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Hospital-Indian Creek Campus
Overland Park, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood, United States
University of Kentucky/Markey Cancer Center
Lexington, United States
The James Graham Brown Cancer Center at University of Louisville
Louisville, United States
UofL Health Medical Center Northeast
Louisville, United States
Tufts Medical Center
Boston, United States
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, United States
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, United States
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, United States
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, United States
Trinity Health Saint Joseph Mercy Oakland Hospital
Pontiac, United States
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, United States
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, United States
Baptist Cancer Center-Grenada
Grenada, United States
Baptist Memorial Hospital and Cancer Center-Union County
New Albany, United States
Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, United States
Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven, United States
Billings Clinic Cancer Center
Billings, United States
Bozeman Health Deaconess Hospital
Bozeman, United States
Benefis Sletten Cancer Institute
Great Falls, United States
Community Medical Center
Missoula, United States
University of Rochester
Rochester, United States
Montefiore Medical Center - Moses Campus
The Bronx, United States
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, United States
Prisma Health Cancer Institute - Easley
Easley, United States
Prisma Health Cancer Institute - Butternut
Greenville, United States
Prisma Health Cancer Institute - Faris
Greenville, United States
Prisma Health Cancer Institute - Eastside
Greenville, United States
Prisma Health Cancer Institute - Greer
Greer, United States
Prisma Health Cancer Institute - Seneca
Seneca, United States
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, United States
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, United States
Gundersen Lutheran Medical Center
La Crosse, United States
Trial contact
Site Public Contact
Yehuda E. Deutsch
PRINCIPAL_INVESTIGATOR
Site Public Contact
John M. Schallenkamp
PRINCIPAL_INVESTIGATOR
Site Public Contact
Yuchen Liu
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jesus Gonzalez Lugo
PRINCIPAL_INVESTIGATOR
Site Public Contact
Fevzi Yalniz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Mohamed M. Hegazi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Andreas K. Klein
PRINCIPAL_INVESTIGATOR
Site Public Contact
Tareq Al baghdadi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Salil Goorha
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Bassil Botros
PRINCIPAL_INVESTIGATOR
Site Public Contact
Ioannis Mantzaris
PRINCIPAL_INVESTIGATOR
Site Public Contact
Suzanne R. Fanning
PRINCIPAL_INVESTIGATOR
Site Public Contact
Michael O. Ojelabi
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.